Literature DB >> 18541460

Lipoxin A(4) and interleukin-8 levels in cystic fibrosis sputum after antibiotherapy.

Raphaël Chiron1, Y Yaël Grumbach, Nga V T Quynh, Valia Verriere, Valérie Urbach.   

Abstract

UNLABELLED: Antibiotics are largely prescribed for cystic fibrosis (CF) respiratory exacerbations. Effects of antibiotics on the inflammatory profile of the patients have been shown but remain controversial. Lipoxin A(4) (LXA(4)) is a lipid mediator, reported to play a central role in resolving airway inflammation. The aim of the study was to investigate the consequences of antibiotherapy on LXA(4) and IL-8 levels in CF patients' airways.
METHODS: Eighteen CF patients (7 females, median age 20, range 8 to 47 years) consecutively admitted at the CF center of Montpellier for antibiotics during pulmonary exacerbation, were enrolled. Before and after antibiotics, all patients underwent spirometry (FEV(1) and FVC), bacterial cultures and cell counts in sputa. IL-8 and LXA(4) concentrations were determined in sputum samples by the median of immunometric assays.
RESULTS: As previously reported, after antibiotics therapy, FEV(1) and FVC significantly improved. While neutrophil cell counts and IL-8 levels decreased, the LXA(4) levels significantly increased after antibiotics therapy and were inversely correlated with IL-8 levels. In conclusion, we reported a correlation between antibiotics treatments and inflammatory markers in CF sputum. Our data provide evidences for a novel effect of antibiotics increasing the concentration of the anti-inflammatory lipid mediator LXA(4).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18541460     DOI: 10.1016/j.jcf.2008.04.002

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  10 in total

1.  Pseudomonas aeruginosa sabotages the generation of host proresolving lipid mediators.

Authors:  Becca A Flitter; Kelli L Hvorecny; Emiko Ono; Taylor Eddens; Jun Yang; Daniel H Kwak; Christopher D Bahl; Thomas H Hampton; Christophe Morisseau; Bruce D Hammock; Xinyu Liu; Janet S Lee; Jay K Kolls; Bruce D Levy; Dean R Madden; Jennifer M Bomberger
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-15       Impact factor: 11.205

2.  Benzyloxycarbonyl-proline-prolinal (ZPP): Dual complementary roles for neutrophil inhibition.

Authors:  D W Russell; M Hardison; K R Genschmer; T Szul; P E Bratcher; M Abdul Roda; X Xu; L Viera; J E Blalock; A Gaggar; B D Noerager
Journal:  Biochem Biophys Res Commun       Date:  2019-08-07       Impact factor: 3.575

3.  Elevated prostaglandin E metabolites and abnormal plasma fatty acids at baseline in pediatric cystic fibrosis patients: a pilot study.

Authors:  Michael Glenn O'Connor; Kelly Thomsen; Rebekah F Brown; Michael Laposata; Adam Seegmiller
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2016-08-27       Impact factor: 4.006

Review 4.  Bronchoprotective mechanisms for specialized pro-resolving mediators in the resolution of lung inflammation.

Authors:  Melody G Duvall; Thayse R Bruggemann; Bruce D Levy
Journal:  Mol Aspects Med       Date:  2017-05-17

Review 5.  Omics approaches in cystic fibrosis research: a focus on oxylipin profiling in airway secretions.

Authors:  Jason P Eiserich; Jun Yang; Brian M Morrissey; Bruce D Hammock; Carroll E Cross
Journal:  Ann N Y Acad Sci       Date:  2012-07       Impact factor: 5.691

6.  Exhaled breath condensate eicosanoid levels associate with asthma and its severity.

Authors:  Shamsah Kazani; Anna Planaguma; Emiko Ono; Matteo Bonini; Muhammad Zahid; Gautham Marigowda; Michael E Wechsler; Bruce D Levy; Elliot Israel
Journal:  J Allergy Clin Immunol       Date:  2013-04-19       Impact factor: 10.793

Review 7.  DHA- and EPA-derived resolvins, protectins, and maresins in airway inflammation.

Authors:  Melody G Duvall; Bruce D Levy
Journal:  Eur J Pharmacol       Date:  2015-11-03       Impact factor: 4.432

8.  Resolvin D1 and Resolvin E1 Promote the Resolution of Allergic Airway Inflammation via Shared and Distinct Molecular Counter-Regulatory Pathways.

Authors:  Bruce D Levy
Journal:  Front Immunol       Date:  2012-12-28       Impact factor: 7.561

Review 9.  Physiological impact of abnormal lipoxin A₄ production on cystic fibrosis airway epithelium and therapeutic potential.

Authors:  Gerard Higgins; Fiona Ringholz; Paul Buchanan; Paul McNally; Valérie Urbach
Journal:  Biomed Res Int       Date:  2015-03-19       Impact factor: 3.411

10.  Candidate markers associated with the probability of future pulmonary exacerbations in cystic fibrosis patients.

Authors:  Gabriella Wojewodka; Juan B De Sanctis; Joanie Bernier; Julie Bérubé; Heather G Ahlgren; Jim Gruber; Jennifer Landry; Larry C Lands; Dao Nguyen; Simon Rousseau; Andrea Benedetti; Elias Matouk; Danuta Radzioch
Journal:  PLoS One       Date:  2014-02-12       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.